MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Research
Written by / Agency / Source: BASF
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BASF and CTIBiotech to Develop First 3D Bioprinted Human Reconstructed Skin Including Immune Macrophages - The new 3D model will allow research and development of anti-inflammatory properties of active ingredients - CTIBiotech.com / BASF.com
BASF and CTIBiotech to Develop First 3D Bioprinted Human Reconstructed Skin Including Immune Macrophages

 

NewswireToday - /newswire/ - Ludwigshafen, Rhineland-Palatinate, Germany, 2019/09/05 - The new 3D model will allow research and development of anti-inflammatory properties of active ingredients - CTIBiotech.com / BASF.com. DE000BASF111

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The joint research of BASF Care Creations® and CTIBiotech is about to reach a new milestone. The cooperation partners announce the development of the first 3D bioprinted skin models including immune macrophages. The reconstructed tissue models will be the basis for development and testing of bio-actives for skin care applications.

Using CTIBiotech’s 3D bioprinting technology will enable BASF’s scientists to increase their 3D bioprinted skin model portfolio. The technology will provide a powerful platform for skin care researchers wishing to study the function of macrophages in a fully reconstructed skin.

Macrophages constantly monitor the skin’s microenvironment for indications of cell stress, tissue injury or infection. They are essential to close wounds and to fully regenerate tissue. To maintain skin homeostasis, macrophages have a high degree of plasticity that promote or suppress inflammation.

“Compared to current in vitro methods, the 3D immune bioprinted skin developed with CTIBiotech will allow analysis more in line with human physiology and the immune role of macrophages,” said Dr Sébastien Cadau, 3D tissue engineering specialist at BASF site in Lyon, France. “That’s how the technology is going to help us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of an immunocompetent 3D skin provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications.”

BASF and CTIBiotech started their cooperation as early as 2011. In 2015, the research partners started working on 3D tissue models for the development and testing of bio-actives for skin care applications. In 2018, they announced first results: The experts demonstrated both the ex vivo production of physiological sebum in a long-term culture of a 3D human sebaceous gland model and the regulation of this sebum production by means of active ingredients.

“CTIBiotech and BASF have a long history of collaborations on innovative human skin models to advance human skin care,” said Prof Colin McGUCKIN, Chief Scientific Officer at CTIBiotech. “CTIBiotech hosts a team of world experts for human tissue engineering with 3D Bioprinting technology that will strengthen the success of this partnership also in the future.”

About BASF

At BASF (basf.com), we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 122,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of around €63 billion in 2018. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S.

About CTIBIOTECH Cell Therapy Research Institute

CTIBiotech (ctibiotech.com) develops and produces predictive models of human tissues and cells for biomedical, pharmaceutical and dermatocosmetic research and development. CTIBiotech hosts a team of world-class experts who have pioneered innovation in bioengineering and regenerative medicine over the past 30 years. CTIBiotech partners with public and private organizations to develop innovative solutions for the efficacy and safety testing of active ingredients, dermatocosmetics, drug candidates, cell therapies and medical devices. CTIBiotech is organized around three Business Units: 1. CTISkin: advanced human skin models to test new product ideas with scientific innovation and credibility for dermatology and cosmetics; 2. CTIPharma: robust and predictive biological bioassays on human cells to accelerate the development of drugs, medical devices and cellular therapies; 3. CTIBiosourcing: manufacturing of biological models, tissues and human cells. More than 50,000 tissue samples in stock or on demand for biosourcing through a network of 200 healthcare partners worldwide.

CTIBiotech Press contact: Dr. Nico Forraz
P: +33(0)6 78 90 38 50 - E: nico.forraz[.]ctibiotech.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: BASF

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


BASF and CTIBiotech to Develop First 3D Bioprinted Human Reconstructed Skin Including Immune Macrophages

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Annika Bröter - BASF.com 
+49 2173 4995-446 annika.broeter[.]basf.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BASF securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BASF / Company Profile


Read Research Most Recent Related Newswires:

Increasing Demand for Real Time Access Boosts the Global Image Recognition Market At 21.00% CAGR According to Inkwood Research
Innovative MYRRHA Research Reactor Starting to Take Shape
BASF and BNP Brinkmann Acting as Project Partners to Support Current DLR Research on the Future of Mobility
Bruker Announces Acquisition of Preclinical and Molecular Imaging Research Software Provider PMOD Technologies, LLC
Rohde & Schwarz and Martin Luther University Halle-Wittenberg Establish Research Partnership
Bruker and Champalimaud Foundation Announce Collaboration to Develop Novel Ultra-High Field 18 Tesla Preclinical MRI System and Applications
Biomedical Software Startup BostonGene Secures M in Series A Financing from NEC
Imec, UZ Leuven, KU Leuven, The Ghent University, Agilent, Western Digital and BlueBee Develop Unique Hybrid Cloud Platform
Digital Revolution - Naval Group, B<>com’s New Industrial Investor
Bruker and the Translational Metabolic Lab At Radboud University Announce the Establishment of A Joint Center of Excellence for Translational Omics
Rohde & Schwarz and Helmut Schmidt University Hamburg Conduct Joint Research
Imec Researcher Receives ERC Advanced Grant to Develop Ultra-bright Thin-film Light Sources and Lasers
DSM Sets Science-based Reduction Targets for Emissions
Novel Nanomaterial Promises Improvements in Batteries and Many More Sustainable Applications
OnePlanet, a New Dutch Innovation Center for Food, Health and Agricultural Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)